BIBF 1120 (Nintedanib) Mechanism of Action: PDGFR Inhibition in Lung Fibroblast Research

BIBF 1120 (Nintedanib) MOA:Targeting PDGFR/PDGF Signaling Pathway for Idiopathic and Progressive Pulmonary Fibrosis

🎯 check BIBF 1120 (Nintedanib) product page

BIBF 1120 (Nintedanib) is a potent, ATP-competitive VEGFR, FGFR, and PDGFR inhibitor. It affects VEGF, FGF, and PDGF signaling, by binding to the kinase ATP-binding clefts, inhibiting angiogenesis, tumor growth, and pulmonary fibrosis.

Primary Applications and Mechanism of Action